Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
Please provide your email address to receive an email when new articles are posted on . Higher end-of-treatment hepatitis B surface antigen level correlated with nucleos(t)ide clinical relapse among ...
(RTTNews) - Vir Biotechnology Inc. (VIR) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results